<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448978</url>
  </required_header>
  <id_info>
    <org_study_id>241-59-88</org_study_id>
    <nct_id>NCT03448978</nct_id>
  </id_info>
  <brief_title>Autologous CD8+ T-cells Transiently Expressing an Anti-BCMA CAR in Patients With Myeloma</brief_title>
  <official_title>Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cartesian Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cartesian Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study will test the safety and anti-myeloma activity of ascending doses of
      Descartes-08 (autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen
      receptor) in eligible patients with active multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]. Descriptive statistics by incidence rate, body system classification, severity, and causality [per protocol definitions]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>IMWG treatment response criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Descartes-08 (cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Descartes-08</intervention_name>
    <description>autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor</description>
    <arm_group_label>Descartes-08 (cells)</arm_group_label>
    <other_name>CAR-T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (condensed):

          -  Multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an
             immunomodulatory drug (IMiD) after at least 2 prior lines of therapy OR have failed at
             least 3 prior lines of therapy

          -  Measurable disease activity as indicated by serum or urine M-protein, serum free light
             chain, biopsy-proven plasmacytoma, &gt;5% bone marrow plasma cells.

          -  Adequate vital organ function as indicated by ANC, ALC, platelet count, hemoglobin,
             serum ALT and AST, total bilirubin, serum creatinine, and cardiac ejection fraction

        Exclusion Criteria (condensed):

          -  Previous receipt of CAR T-cells or anti-BCMA therapy

          -  History of allogeneic stem cell transplant

          -  Plasma cell leukemia

          -  Pregnant or lactating

          -  Active, uncontrolled infection

          -  Active and severe auto-immune disease

          -  Active arrhythmia, or obstructive or restrictive pulmonary disease

          -  Central nervous system disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Metin Kurtoglu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cartesian Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Choquette, MSN, RN, CCRC</last_name>
    <phone>571-389-0873</phone>
    <email>Karin.Choquette@usoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virgina Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Choquette, MSN, RN, CCRC</last_name>
      <phone>571-389-0873</phone>
      <email>Karin.Choquette@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Gregory J. Orloff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

